In 2003, a research study began that is evaluating the safety of an experimental vaccine for Ebola in humans. The trial vaccine, which is a type of DNA vaccine, is similar to other investigational vaccines that hold promise for controlling such diseases as AIDS, influenza, malaria, and hepatitis.
This experimental vaccine does not contain any infectious material from the Ebola virus. The candidate Ebola vaccine is synthesized using modified, inactivated genes from the virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered.